Our pipeline
Delivering first-in-class immunotherapies
of activation and regulation

OSE Immunotherapeutics’ team has unique expertise and experience in immunological target discovery that serves as the basis for the development of innovative agonists and antagonists for application in immuno-oncology and autoimmune diseases.

OSE Immunotherapeutics has a balanced clinical and preclinical portfolio of products with a diversified risk profile.

OSE Immunotherapeutics’ R&D expertise in immunology has translated into several first-in-class products that activate or regulate the immune system and are being developed in a wide range of clinical indications. Its approach has been validated through partnerships with academic institutions and leading global pharmaceutical companies.

OSE Immunotherapeutics has a proven ability to deliver novel therapeutic products from target identification to clinical outcomes:

•  Phase 3 asset (Tedopi^®) with positive Step-1 results in non-small cell lung cancer post-checkpoint inhibitor therapy: Primary endpoint met: demonstrated 12-month overall survival rate in Tedopi^® treated patients – Results at ESMO 2020
• 4 clinical stage assets in immuno-oncology and auto-immunity
  And a second generation COVID-19 prophylactic vaccine program with positive results in preclinical and human ex vivo settings.
• 3 areas of expertise within our immunology research platform: T-cell-based vaccination, immuno-oncology (focus on myeloid targets), and auto-immunity & inflammation.

Endorsed by significant partnerships with Servier and Boehringer Ingelheim for up to €1.3Bn in milestones (€60 M already received since 2016)